Nonmetastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, MD, PhD


June 30, 2020

For men with early, localized prostate cancer, immediate androgen suppression after radiotherapy significantly improves disease-free and overall survival. These tumors, however, can become resistant to androgen deprivation therapy over time.

In this ReCAP, Professor Johann de Bono of The Institute of Cancer Research, in London, discusses improvements in chemical castration and improved survival benefits from androgen receptor antagonist therapy in men with rising PSA levels. He also reports on updated trials looking at apalutamide, enzalutamide, and darolutamide, from ASCO 2020.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.